Project LUCAS.

Approximately 5,400 people die each year from lung cancer in the Czech Republic.

It's sad primacy among all tumors.

The illness is mostly diagnosed late.

Only 1 out of 8 patients live more than 5 years after diagnosis.

The patients prognosis is improving with new treatment modalities.

the only project of its kind that is mapping the patient's complex path from diagnosis

a prospective study adapting new technologies

Let´s give timely and adequate care in line with scientific knowledge to our patients!

Number of patients included in the monitoring of 8/12/2023:

8 118

News

First article with LUCAS results has been published in Anticancer Research

11/4/2021

First article with LUCAS results has been published in Anticancer Research: "Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry" written by authors Venclicek et al.
Link to the article here.

ZP MV CR will support LUCAS project – complex and quality care for lung cancer patients

9/3/2020

Health insurance company of the Ministry of Interior (ZP MV CR) signed a Memorandum with Czech pulmology and phtizeology society (CPFS), company OAKS Consulting s.r.o. (OAKS) and Czech Medical Association of J. E. Purkyně (CzMA) on August 27, 2020 to cooperate on LUCAS project (LUng CAncer focuS).

ZP MV CR will support LUCAS project – complex and quality care for lung cancer patients

More news

prof. Martina Vasakova, Ph.D.

Chairman of the Czech Pneumology and Phtizeology society

Projects outputs About project Projects partners

Lung cancer

The cause of this disease is probably multifactorial, however, approximately 85% of deaths from lung cancer are attributable to cigarette smoking.

Symptoms include persistent cough, blood coughing, repeated lung infections, weight loss, shortness of breath.

The diagnosis is made at late stages of the disease.

Therapies have expanded considerably in recent years and now include surgery, radiotherapy, chemotherapy, targeted treatment and immunotherapy.

The tumors that can be surgically removed account only for 10-15% cases.

Targeted treatment and immunotherapy are gaining importance, as they can prolong the life by as much as few years.

Lung cancer is the most common cause of cancer death.

Czech Pneumology and Phtizeology society launched the LUCAS project od June 1, 2018.

The objective is to secure complex reimbursed care in line with guidelines and scientific knowledge.

What is a fast and accurate diagnosis?

Which tests and examinations lead us to the right decision?

How long after diagnosis is it necessary to begin treatment to reverse the prognosis?

What treatment sequences are the most effective in the given patient types?

What if someone in my family gets sick?

Can I rely on getting the best care?

What is the standard of treatment guaranteeing the longest possible quality of life?

Participating centers

Number of patients included in the monitoring of 8/12/2023:

8 118

13 centers are currently participating in the LUCAS project:
Thomayer hospital Praha
University hospital Brno
University hospital Olomouc
University hospital Hradec Kralove
University hospital Motol Praha
University hospital Plzen
University hospital Bulovka Praha
Hospital Jihlava
Hospital Agel Ostrava-Vitkovice
Hospital Liberec
Hospital Pardubice
General university hospital
Masaryk Memorial Cancer Institute

Goals

Obtaining information on all patients with newly diagnosed lung cancer in centers and their monitoring in lifelong perspective
Continuous data analysis, processed with a half-year periodicity
Publications of the results of the analyzes in professional journals
Evaluation of the extent and structure of care provided, treatment management, treatment sequences, overall survival and progression-free survival
Pharmaco-economic evaluation of lung cancer patients care

The course of the project

The LUCAS project is a non-interventional follow-up of patients with newly diagnosed lung cancer in lifelong perspective.
LUCAS is collecting comprehensive data on the diagnosis and treatment of these patients in selected pneumology centers.

Outputs

ČPFS is continuously analysing data from the LUCAS project and evaluating the extent and structure of care for patients with lung cancer.
Data from the LUCAS are used for expert opinions used in administrative proceedings.
Interactive dashboards are available on a monthly basis:
Diagnostics

baseline characteristics of the patient and initial diagnosis, patient flow, potential for treatment already on the market and for market access and pre-launch activities as well as for new entrants, identification of space for optimization of diagnostic procedures

Pharmacotherapy, Intervention

patient flow, treatment sequences, used modalities and their combinations (incl. proportion of untreated patients) potential of number of patients for first, second and next pharmacotherapy, determination of comparator, quantification of number of patients who really received treatment for a given subpopulation

Timeline

timeline from diagnosis through individual interventions in the lifelong horizon, sequence of interventions, time to start of treatment, time to treatment, time to progression, number of patients on selected treatment, proportion of deaths

Publications

Venclicek et al: Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry. Anticancer Research November 2021, 41 (11) 5549-5556;

Marel et al: Worse Prognosis in the Symptomatic Patients With Lung Cancer - Czech Multicentric Study. Cancer Diagnosis & Prognosis, Vol 2(2) 167-172

Svaton et al: Laboratory parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer. Anticancer Research March 2022, 42 (3) 1563-1569

Partners

The project originated and is implemented in cooperation with OAKS Consulting, who is responsible for project management, outputs processing and who significantly supports the project financially.